Recardio

Regenerative Cardiac

  • About Us
    • Profile
    • Management
    • Boards
    • Awards
  • Science
    • Approach
    • Background
    • Therapy
  • Clinical
    • Phase 1
    • Phase 2B AMI
    • Phase 2B CHF
  • News Center

Jun 01 2022

Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design

San Francisco, June 1, 2022 – Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio’s pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction.  

Read More

Written by Recardio · Categorized: Uncategorized

May 23 2022

Recardio’s Positive Phase 2 Results presented as Latebreaker at World Congress on Heart Failure 2022 in Madrid


San Francisco, May 23, 2022 – Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio’s Phase 2 clinical study in Acute Myocardial Infarction were presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid. 

Read More

Written by Recardio · Categorized: Uncategorized

Mar 28 2022

Recardio at BIO-Europe Spring 2022

San Francisco, March 28, 2022 – Recardio Inc., a late stage clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, is participating at the BIO-Europe Spring 2022.

Read More

Written by Recardio · Categorized: Uncategorized

Jan 10 2022

Recardio at J.P. Morgan Conference 2022

San Francisco, January 10, 2022 – Recardio Inc., a late-stage clinical-stage life science company focusing on therapies for cardiovascular diseases, is participating in the 40th Annual J.P. Morgan Healthcare Conference in San Francisco.

Read More

Written by Recardio · Categorized: Uncategorized

  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2022 · All Rights Reserved

Copyright © 2022 · Recardio on Genesis Framework · WordPress · Log in